UNSPSC 51441619: Radium-223 dichloride

Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223. It is used to treat prostate cancer that has spread to the bones and cannot be treated with surgery and is used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases.

UNSPSC 51441619 Radium-223 dichloride is a Commodity code representing a specialized pharmaceutical product used in oncology and nuclear medicine applications. State and local procurement activity under this code is minimal; the recent opportunities block contains no active solicitations for radium-223 dichloride or closely related radiopharmaceuticals. The posted opportunities span vendor networking events, pharmaceutical procurement for emergency medical services and forensic analysis, generic drug supply contracts, and informational forums—none of which involve radium-223 dichloride specifically. The code shows no current state or local government demand signals in the available record.

The absence of recent state and local procurement for radium-223 dichloride reflects the highly specialized nature of this radiopharmaceutical, which is typically supplied through regulated nuclear pharmacy channels and purchased by hospital oncology departments or specialized cancer treatment centers rather than through general state and local procurement processes. Business development professionals should monitor this code for future activity but should not expect frequent or high-volume solicitation under UNSPSC 51441619 through standard state and local government channels. Opportunities in this space are more likely to surface through direct relationships with healthcare systems, teaching hospitals, and cancer research institutions than through public RFP or RFQ notice cycles.